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Abstract
Background: Knowledge of the factors associated with health-related quality of life (HRQOL) among patients with
thalassemia is essential in developing more suitable clinical, counseling, and social support programs to improve
treatment outcomes of these patients. In light of the limited research in this area, this study aims to examine
factors associated with HRQOL among children and adolescents with thalassemia in Thailand.
Methods: A cross-sectional survey was conducted in three selected hospitals in Thailand during June to November
2006. PedsQL™ 4.0 Generic Core Scale (Thai version) was used to assess HRQOL in 315 thalassemia patients
between 5 and 18 years of age. Other related clinical characteristics of the patients were collected via medical
record review.
Results: The mean (SD) of the total summary score was 76.67 (11.40), while the means (SD) for the Physical Health
Summary score and Psychosocial Health Summary score were 78.24 (14.77) and 75.54 (12.76), respectively. The
school functioning subscale scored the lowest, with a mean of 67.89 (SD = 15.92). The following factors
significantly affected the HRQOL of the patients: age; age at onset of anemia and age at first transfusion; pre-
transfusion hemoglobin (Hb) level; receiving a blood transfusion during the previous three months; and disease
severity. In addition, iron chelation therapy had a significant negative effect on HRQOL in the school functioning
subscale. In contrast, serum ferritin level, frequency of blood transfusions per year, and gender were not
significantly related to HRQOL among these patients. The results from multivariate analysis also confirmed these
findings.
Conclusions: To improve HRQOL of thalassemia patients, suitable programs aimed at providing psychosocial
support and a link between the patient, school officials, the family and the physician are important, especially in
terms of improving the school functioning score. The findings also confirmed the importance of maintaining a pre-
transfusion Hb level of at least 9-10.5 g/dL. In addition, special care and attention should be given to patients with
a severe condition, and those who are receiving subcutaneous iron chelation therapy.
Background
Thalassemia is an inherited blood disease. It is a serious
public health problem throughout the Mediterranean
region, the Middle East and the Indian subcontinent, as
well as in Southeast Asia [1]. Out of approximately 300
million carriers of this hemoglobin disorder worldwide
[2], 55 million live in Southeast Asia [3]. In Thailand,
with a population of 65 million, about 40% have
thalassemia traits or are carriers, while 1% of the popu-
lation is afflicted with this disease [4].
Thalassemia is a chronic disease that presents a range
of serious clinical and psychological challenges. The
effects of thalassemia on physical health can lead to
physical deformity, growth retardation, and delayed pub-
erty [5-7]. Its impact on physical appearance, e.g., bone
deformities and short stature, also contributes to a poor
self-image [6,7]. Severe complications such as heart fail-
ure, cardiac arrhythmia, liver disease, endocrine compli-
cations, and infections are common among thalassemia
patients [8,9]. The problems mentioned do not only
affect patients’ physical functioning but also their
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functioning, leading to impaired health-related quality of
life (HRQOL) of the patients [6,7,10-14].
Although thalassemia is recognized as a genetic blood
disorder which can be fatal if proper treatment is not
received, during the past decades the development of
new treatments and clinical management has markedly
improved the prognosis as well as the survival rates of
the patients [9,15-18]. However, the positive impact of
these treatments is likely to be diminished, especially in
terms of HRQOL, if they interfere with daily activities
or are less tolerable. These may be the cases of regular
blood transfusions that require frequent visits to the
hospital, and nightly subcutaneous injections of iron
chelation therapy [14].
For chronic diseases such as thalassemia, where a cure
is not attainable and treatment may be prolonged,
HRQOL is likely to be an essential outcome when con-
sidering options for treatment for individual patients
and the allocation of health care resources. In child
health service research, HRQOL is also recognized as an
important health outcome [19-21]. As children are less
able to voice their concerns and are more vulnerable
than adults, the assessment of HRQOL in children is
essential for the provision of proper care, since it helps
in identifying the impacts of the disease and treatment
from the children’s perspective. Moreover, a recent
study found that HRQOL of children can be used as a
predictor of health care costs, and can also help identify
at-risk groups of children who are candidates for proac-
tive care coordination [22].
Due to the effects of the disease and its treatment, as
mentioned previously, existing evidence indicates that
thalassemia has a negative impact on HRQOL [6,11-13].
A previous study revealed that thalassemia patients
experienced more depressive symptoms and reported
lower HRQOL [6]. In addition, it was found that not
only transfusion-dependent patients but also transfu-
sion-independent patients suffered from impaired
HRQOL [12]. By using EuroQoL (EQ-5D), a prior study
[13] found that the pain domain of patients was affected
the most, followed by the depression and mobility
domains, with an equal score. One study [12] found that
the most commonly affected domains were feelings such
as depression, anxiety, and concern about overall health
status; while another study [11] found that quality of life
in the school domain was affected the most.
Presently, there is limited research examining the fac-
tors associated with HRQOL in children and adolescents
with thalassemia. A previous study conducted in adults
with thalassemia found that treatment and cultural dif-
ference did not affect HRQOL [7]. Other studies have
found that age [11] and side effects of iron chelation
[13,14] are predictors of HRQOL in children with tha-
lassemia; while gender, ethnicity and household income
are not [13]. A better understanding of the factors asso-
ciated with HRQOL among children and adolescents
with thalassemia could have a direct effect on the devel-
opment of more suitable clinical, counseling, and social
support programs to enhance treatment outcomes, espe-
cially in terms of HRQOL of these patients. In addition,
at-risk groups of children and adolescents could be
identified as candidates for proactive care assistance.
Given the insufficient research in this area, this study
aims to examine factors associated with HRQOL among
thalassemic children and adolescents with the focus on
patient perspective.
Methods
Participants and settings
The cross-sectional study was conducted among chil-
dren and adolescents with thalassemia who received
outpatient treatment at one of three participating hospi-
tals - Phramongkutklao Hospital, King Chulalongkorn
Memorial Hospital, and Saraburi Hospital - from June
to November 2006. Phramongkutklao Hospital and King
Chulalongkorn Memorial Hospital are teaching hospitals
located in Bangkok, while Saraburi Hospital is a regional
hospital located in Saraburi province (108 km from
Bangkok). Participants in the study were selected based
on the inclusion and exclusion criteria specified in
Table 1. The demographic characteristics for the sample
were later described in Table 2.
The sample size required for the study was calculated
using the formula by Lemeshow et al. [23]. According to
the formula, sample size should not be smaller than 30
times the total number of independent variables. Since
the number of independent variables in this study is
approximately 11, the total sample size required was
330.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients diagnosed with thalassemia. Patients having impaired cognitive function or having severe clinical
condition, which may limit their ability to participate in the study.
Patients between 5 and 18 years of age. Patients taking oral iron overload treatment.
Patients who had been treated at Phramongkutklao Hospital, King
Chulalongkorn Memorial Hospital or Saraburi Hospital since October 1,
2004.
Patients unwilling to participate in the study.
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In this study, quality of life assessment was performed
using the Pediatric Quality of Life Inventory™ (PedsQL™)
4.0 Generic Core Scale (Thai version). A user agreement
was signed with the MAPI research Institute, Lyon,
France, prior to use of the questionnaire. The PedsQL
4.0 Generic Core Scale includes parallel child self-
reports (age ranges 5-7, 8-12 and 13-18 years) and par-
ent proxy-reports (age ranges 2-4, 5-7, 8-12 and 13-18
years). PedsQL items ask how much of a problem a par-
ticular thing has been for patients during a certain
period (the standard recall period is the past month).
Item responses are measured on a five-point rating scale
ranging from 0 (never a problem) to 4 (almost always a
problem). The 23 items consist of 8 items on physical
functioning, 5 items on emotional functioning, 5 items
on social functioning and 5 items on school functioning,
yielding a total score and two summary scores (i.e., Phy-
sical Health and Psychosocial Health). Each scale has a
score ranging from 0-100, the higher score indicating
higher QOL. The original version of PedsQL has
demonstrated good internal consistency and validity in
Table 2 Patient characteristics
N (%)/Mean (SD)
Gender (n = 314)
Male 159 (50.6%)
Female 155 (49.4%)
Age (years) (n = 315) 10.0 (3.3)
Diagnosis (n = 310)
b-thalassemia/Hb E 165 (53.2%)
Homozygous b-thalassemia 15 (4.8%)
Hemoglobin H 130 (42%)
Age at onset of anemia (years)
(n = 270)
3.61 (2.6)
Age at first transfusion (years)
(n = 191)
3.91 (2.8)
Receiving a blood transfusion during the previous 3 months
(n = 245)
Yes 103 (42%)
No 142 (58%)
Frequency of blood transfusion
(n = 312)
None 146 (46.8%)
Occasional (1-5 times/year) 58 (18.6%)
Low (6-12 times/year) 77 (24.7%)
High (13-22 times/year) 31 (9.9%)
Pre-transfusion Hb level 3 months prior to QOL assessment (g/dL)
(n = 265)
8.04 (1.2)
Serum ferritin level (ng/mL) (n = 127) 2509.9(1903.6)
Iron chelation treatment (n = 314)*
Yes 86 (27.4%)
No 228 (72.6%)
Complications (n = 314)
Yes 19 (6.1%)
No 295 (93.9%)
Age at onset of anemia <2 and age at first transfusion <4 years old
(n = 241)
Yes 75 (31.1%)
No 166 (68.9%)
Having a severe condition** (n = 314)
Yes 113 (36%)
No 201 (64%)
* Subcutaneous injection treatment
** Patients whose age at onset <2 and age at first transfusion <4 years, and/or patients diagnosed with homozygous beta-thalassemia, and/or patients with a
pre-transfusion Hb level lower than 7 g/dL.
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conditions, as well as in samples of healthy children and
adolescents [24-26]. Furthermore, previous use of the
PedsQL 4.0 Generic Core Scale (Thai version) in Thai-
land indicated that it could distinguish between normal
children and those with attention-deficit hyperactivity
disorder (ADHD) [27].
Apart from the PedsQL questionnaire, the other instru-
ment used in this study was a clinical record form. This
form consisted of questions concerning demographics of
the patients (e.g., gender, age, type of payment, hospital
name, etc.), and clinical information (e.g., onset of ane-
mia, diagnosis, age at first transfusion, history of blood
transfusion, hemoglobin (Hb) level, complications, serum
ferritin level, iron chelation treatment, etc.).
Data collection
All eligible patients and their parents were approached
as they came in for routine follow-ups at the thalassemia
clinic in the Department of Pediatrics of each hospital
during the data collection period. Written parental
informed consent and the child’s assent were obtained
prior to participating in the study. At the beginning of
the interview, all respondents were informed of the
objectives of the study and were assured that all
responses would remain confidential. For HRQOL
assessment, the PedsQL questionnaires were to be com-
pleted independently by children with a minimum age
of 8 years. Children aged 5-7 years were interviewed by
trained interviewers. A clinical record form was then
completed via medical record review for all patients in
the study. The study was approved by the ethics com-
mittee of each participating hospital namely, Institu-
tional Review Board of the Royal Thai army of Medical
Department, Institutional Review Board of the Faculty
of Medicine, Chulalongkorn University, and Institutional
Review Board of Saraburi hospital.
Data analysis
Data were analyzed by Microsoft Excel 2003 and SPSS
(Statistical Package for the Social Sciences) program ver-
sion 13.0. General characteristics of the patients were
presented in terms of percentage, mean, and standard
deviation. For HRQOL, both total HRQOL score and
summary scores were presented in terms of mean and
standard deviation. Pearson’s correlation, chi-square,
ANOVA, and T-test were used to examine the relation-
ship between HRQOL and each demographic/clinical
factor. Nonparametric tests were used if data were not
normally distributed. Factors influencing the quality of
life of children with thalassemia were later examined by
multiple regression analysis.
Since a serum ferritin level above 2,500 ng/mL is asso-
ciated with cardiovascular disease [15,16,28] and
mortality [15], for data analysis serum ferritin level was
classified into two levels: ≤2,500 ng/mL and > 2,500 ng/
mL. With respect to pre-transfusion Hb level, pre-trans-
fusion Hb of less than 7 g/dL indicates a need for regu-
lar blood transfusions. Also, pre-transfusion Hb level
should be monitored routinely to maintain an optimal
l e v e lo f9 - 1 0 . 5g / d L[ 1 5 , 2 9 ] .A sar e s u l t ,i nt h i ss t u d y ,
pre-transfusion Hb was classified into three levels (i.e.,
<7 g/dL, 7-9 g/dL, and >9 g/Dl), In the classification of
severity, the criteria used to determine severity in this
s t u d yw e r ep r e - t r a n s f u s i o nh e m o g l o b i nl e v e l ,a g ea t
onset of anemia and age at first transfusion, and type of
diagnosis. Since there was no consensus on classification
of severity among thalassemia patients, for this study,
the patient was classified as having a severe condition if
any of the following applied: 1) his/her age at onset of
anemia was less than 2 years, and age at first transfusion
w a sl e s st h a n4y e a r s ;2 )ap r e -transfusion hemoglobin
level <7 g/dL; or 3) having been diagnosed with homo-
zygous b-thalassemia (thalassemia major). Age at onset
of anemia and age at first transfusion was used as one
of the criteria, since a previous study [30] found it to be
an important factor in predicting severity among thalas-
semia patients. In addition, Hb level was also used to
classify severity of thalassemia in previous study [30].
Similarly, patient with homozygous b-thalassemia (tha-
lassemia major) was also classified as severe thalassemia
as they required chronic blood transfusion.
Results
Demographic and clinical characteristic of the 315 tha-
lassemic children and adolescents are presented in
Table 2. It was found that about 51% of the participants
were male. The percentages of patients diagnosed with
b-thalassemia/HbE, homozygous b-thalassemia, and
Hemoglobin H were about 53%, 5% and 42%, respec-
tively. The mean age (SD) of the patients was 10 (3.3)
years. About 42% of the patients had received a blood
transfusion during the three months prior to the inter-
view, while only 27% of them had received iron chela-
tion therapy. Mean pre-transfusion Hb level (SD)
measured three months prior to the HRQOL assessment
was approximately 8.04 (1.2) g/dL, while mean serum
ferritin level (SD) was approximately 2,510 (1,903) ng/
mL. Only 6% of the patients reported having complica-
tions. Approximately 36% of the patients were classified
as having a severe condition, as defined above.
HRQOL scores based on child self-reports are pre-
sented in Table 3. Mean (SD) of the total summary
score was 76.67 (11.40). When looking at the two sum-
m a r ys c o r e s ,i tw a sf o u n dt h a tt h em e a n s( S D )o ft h e
Physical Health summary score and Psychosocial Health
summary score were 78.24 (14.77) and 75.54 (12.76),
respectively. For the subscales of Psychosocial Health,
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lowest (mean = 67.89; SD = 15.92), followed by emo-
tional functioning (mean = 75.90; SD = 16.62) and social
functioning (mean = 83.71; SD = 14.73).
Table 4, 5, and 6 present HRQOL scores from the
child self-report, classified by demographic, clinical, and
treatment characteristics of the patients, respectively. As
shown in table 4, age was found to be significantly asso-
ciated with total summary score. The findings indicated
that older patients were more likely to have significantly
higher HRQOL compared to their younger counterparts.
As displayed in table 4, the means of the HRQOL total
summary scores (SD) for children aged 5-7, 8-12 and
13-18 years old were 73.91 (11.79), 75.51 (11.34) and
80.22 (10.44), respectively. On the other hand, gender
was not associated with HRQOL scores.
Regarding clinical characteristics, having severe condi-
tion, pre-transfusion Hb level, age at onset of anemia
and age at first transfusion were found to be significant
predictors of total summary scores, as indicated in table
5. The study revealed that patients whose Hb level was
higher than 9 g/dL had significantly higher total sum-
mary score (mean = 79.82; SD = 10.21) than those with
Hb levels of 7-9 g/dL (mean = 75.59; SD = 11.09) or
less than 7 g/dL (mean = 73.51; SD = 13.06). In addi-
t i o n ,I tw a sf o u n dt h a tp a t i e n t sw h o s ea g ea to n s e to f
anemia was <2 years and age at first transfusion <4
years had significantly low total summary scores. With
regard to severity, it was found that the patients who
were classified as having a severe condition had signifi-
cantly low total summary score than their non-severe
counterparts. On the other hand, diagnosis, complica-
tion, and serum ferritin level were not associated with
HRQOL scores.
For treatment characteristics, receiving a blood trans-
fusion during the previous three months was signifi-
cantly associated with the total summary score, as
shown in table 6. The study indicated that patients who
had received a blood transfusion during the three
months prior to HRQOL assessment had significantly
lower total summary scores, as compared to those who
did not receive a blood transfusion. On the other hand,
frequency of blood transfusion was not associated with
HRQOL scores.
When looking at each summary score, it was found
that two factors - age at onset of anemia and age at first
transfusion, and receiving a blood transfusion during the
previous three months - were significantly related to the
Physical Health summary score; while age and pre-trans-
fusion Hb level were significantly related to the Psycho-
social Health summary score. For the social and school
functioning subscales, age, pre-transfusion Hb level, age
at onset of anemia and age at first transfusion, and
severity were significant predictors of HRQOL. In addi-
tion, iron chelation treatment was significantly asso-
ciated with impaired HRQOL in the school functioning
subscale.
Relationships between HRQOL score and patient
characteristics were presented in Table 7, in terms of
Pearson’s correlation coefficient. Similar to what is
shown in Table 4, 5, and 6, it was found that age and
pre-transfusion Hb level were significant predictors of
HRQOL, while serum ferritin level was not.
Table 8 presents the results of multivariate regression
analysis in examining factors associated with the total
Table 3 Quality of life scores of child self-report
Scale Child self-report (n = 315)
Mean ± SD
Total summary score 76.67 ± 11.40
Physical health 78.24 ± 14.77
Psychosocial health 75.54 ± 12.76
Emotional functioning 75.90 ± 16.62
Social functioning 83.71 ± 14.73
School functioning 67.89 ± 15.92
Table 4 Quality of life scores of child self-report classified by demographic characteristics
Child self-report
Total summary
score
Physical health Psychosocial
health
Emotional
functioning
Social
functioning
School
functioning
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age: years (n = 315)
5-7 n = 63 73.91(11.79) 74.80(16.57) 73.44(13.09) 73.17(19.24) 82.06(17.15) 65.08(16.35)
8-12 n = 153 75.51(11.34) 77.81(14.82) 74.17(12.57) 75.03(16.36) 81.70(14.77) 66.11(16.41)
13-18 n = 99 80.22(10.44) 81.09(12.96) 78.99(12.26) 78.99(16.36) 87.88(12.04) 72.42(13.97)
P-value 0.001 0.054 0.003 0.138 0.003 0.003
Gender (n = 314)
Male n = 159 78.87(11.31) 78.79(14.77) 75.86(11.15) 77.42(15.54) 83.58(13.63) 66.51(16.71)
Female n = 155 76.42(11.54) 77.64(14.83) 75.11(14.24) 74.26(17.58) 83.81(15.85) 69.26(15.05)
P-value 0.701 0.460 0.760 0.101 0.434 0.108
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significant predictors of HRQOL (i.e., total summary
score). The findings revealed a positive relationship
between age and HRQOL (b = 0.243, p < 0.001). Simi-
larly, a significant relationship was also found between
severity and HRQOL (b = -0.162, p = 0.003).
Discussion
Since the focus of this study was on patient perspective
then only HRQOL scores obtained from child self-
report were examined. While data on parent proxy-
report were also collected they will be the focus of sub-
sequent manuscript and will be available upon request.
Similar to what was found in a previous study [11],
the assessment of HRQOL of thalassemia patients in
this study showed that psychosocial health had a lower
score than physical health. Also, as with the previous
study [11], the school functioning subscale scored the
lowest. This could be explained by the fact that frequent
absenteeism from school for hospital visits, and a lack of
energy when performing academic activities, had a sig-
nificant negative impact on the children’s HRQOL
[11,31-33].
Although the pattern of HRQOL scores was found to
be the same as in a previous study [11], HRQOL scores
obtained from this study were somewhat higher. Based
on the previous study[11], the mean total summary
score (SD), mean Physical health summary score (SD),
and mean Psychosocial health summary score (SD) were
67.70 (12.40), 69.17 (15.34), and 67.39 (13.24), respec-
tively. However, due to the absence of HRQOL scores
of healthy children in Thailand as well as differences in
country-specific characteristics, direct comparisons
could be made with caution. Nevertheless, possible
Table 5 Quality of life scores of child self-report classified by clinical characteristics of the patients
Child self-report
Total summary
score
Physical
health
Psychosocial
health
Emotional
functioning
Social
functioning
School
functioning
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Diagnosis (n = 310)
b-thalassemia n = 165 76.23(11.99) 77.46(13.20) 74.74(13.20) 76.03(17.36) 83.60(15.57) 67.06(14.92)
Homozygous b-
thalassemia
n = 15 71.81(10.83) 73.54(13.91) 71.89(12.89) 70.00(16.58) 80.00(13.70) 62.67(15.68)
Hb H n = 130 77.54(10.72) 79.49(14.68) 76.63(12.28) 76.23(15.76) 84.04(13.67) 69.23(17.19)
P-value 0.145 0.187 0.234 0.368 0.424 0.103
Age at onset of anemia <2 and age at first transfusion <4 years old (n = 241)
Yes n = 75 72.75(11.33) 73.96(15.95) 73.51(12.64) 74.53(14.71) 78.53(17.10) 63.26(14.94)
No n = 166 77.72(11.08) 79.01(14.67) 76.02(12.73) 76.08(15.99) 85.49(13.45) 69.52(16.15)
P-value 0.002 0.023 0.099 0.228 0.003 0.003
Complications (n = 314)
Yes n = 19 77.52(14.37) 77.14(19.05) 77.81(16.21) 76.32(19.57) 84.21(16.52) 72.63(15.13)
No n = 295 76.60(11.22) 78.30(14.50) 75.34(12.52) 75.83(16.46) 83.66(14.66) 67.56(15.97)
P-value 0.773 0.941 0.169 0.628 0.661 0.228
Having a severe condition* (n = 314)
Yes n = 113 74.07(12.05) 75.97(15.93) 74.12(12.77) 75.53(15.27) 78.89(16.86) 63.73(16.98)
No n = 201 78.10(10.79) 79.49(15.93) 76.26(12.71) 76.04(17.37) 86.39(12.68) 69.63(15.09)
P-value 0.004 0.077 0.097 0.417 <0.001 0.021
Serum ferritin level (n = 127)
<2500 ng/mL n = 79 76.50(12.83) 78.20(15.66) 75.25(13.38) 74.18(18.70) 84.24(15.19) 66.27(14.82)
>2500 ng/mL n = 48 76.61(10.14) 76.88(13.03) 75.76(12.73) 80.42(14.39) 84.06(13.94) 64.89(15.38)
P-value 0.0897 0.426 0.903 0.100 0.726 0.741
Pre-transfusion Hb level 3 months prior to QOL assessment (n = 265)
<7 g/dL n = 49 73.51(13.06) 75.06(17.84) 73.82(13.41) 74.03(14.21) 76.84(16.64) 64.90(18.78)
7-9 g/dL n = 159 75.59(11.09) 77.10(14.61) 73.78(13.21) 87.01(13.09) 84.03(14.08) 66.00(15.55)
>9 g/Dl n = 57 79.82(10.21) 81.03(13.35) 79.18(17.44) 76.49(17.44) 87.01(13.09) 74.03(14.21)
P-value 0.012 0.163 0.016 0.474 0.002 0.008
* Patients whose age at onset <2 and age at first transfusion <4 years, and/or patients diagnosed with homozygous b-thalassemia, and/or patients with
a pre-transfusion Hb level lower than 7 g/dL
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scores between the two studies was that the patients in
this study represented milder cases of thalassemia, as
compared to those in the previous study [11]. About
60% of patients in the previous study were diagnosed
with homozygous b-thalassemia, and 77% were transfu-
sion-dependent. In contrast, only 4.8% of the patients in
this study were diagnosed with homozygous b-thalasse-
mia, and only 42% had received a blood transfusion dur-
ing the previous three months.
Consistent with the findings from several studies con-
ducted on other diseases [34-37], this study found that
pre-transfusion Hb level and receiving a blood transfu-
sion during the three months prior to HRQOL assess-
ment were significant predictors of HRQOL among
thalassemia patients. This could be explained by the fact
that lower Hb level is associated with a number of
symptoms, such as fatigue, general weakness, and
decreased mental alertness, which might lead to
impaired HRQOL of the patients in several domains.
Similar to the recommendation for blood transfusion
mentioned earlier - that pre-transfusion Hb level should
be monitored routinely to maintain an optimal level of
9-10.5 g/dL [15,29] - the findings of this study indicated
that patients with a pre-transfusion Hb level >9 g/dL
had significantly higher HRQOL than patients whose
pre-transfusion Hb level was <9 g/dL. In the case of
blood transfusion, one possible explanation for the sig-
nificant relationship between receiving a blood transfu-
sion and lower HRQOL is that patients who received
blood transfusions during the three months prior to
HRQOL assessment were those with low pre-transfusion
Hb levels. In contrast, this study found no significant
relationship between frequency of blood transfusion per
year and HRQOL. This non-significant relationship
could be due to the fact that the questions used to
assess HRQOL of the patients were related to the feel-
ings and conditions of the patients during the previous
month; therefore the number of transfusions per year
might not be relevant to the HRQOL score.
Consistent with a previous study [11], age was a sig-
nificant predictor of HRQOL among thalassemia
Table 6 Quality of life scores of child self-report classified by treatment characteristics of the patients
Child self-report
Total summary
score
Physical
health
Psychosocial
health
Emotional
functioning
Social
functioning
School
functioning
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Receiving a blood transfusion during the previous 3 months (n = 245)
Yes n = 103 74.49(12.58) 75.00(16.19) 74.54(13.12) 74.85(18.37) 82.67(16.04) 65.15(16.90)
No n = 142 78.51(10.55) 80.74(13.07) 76.84(12.53) 76.79(16.10) 85.35(13.18) 69.82(15.47)
P-value 0.027 0.008 0.187 0.615 0.320 0.079
Frequency of blood transfusion (n = 312)
None n = 146 78.05(10.77) 79.77(13.25) 76.76(12.53) 76.30(16.61) 85.68(13.55) 69.42(16.92)
Occasional n = 58 76.52(10.86) 78.50(15.77) 74.37(12.40) 74.91(15.55) 82.33(15.59) 69.14(13.48)
Low n = 77 75.06(11.97) 76.70(15.52) 74.13(13.78) 75.71(17.69) 81.16(15.47) 65.65(15.65)
High n = 31 76.44(12.38) 76.91(16.00) 76.45(17.33) 76.45(17.33) 85.65(13.84) 66.45(14.21)
P-value 0.42 0.62 0.45 0.72 0.13 0.26
Iron chelation treatment* (n = 277)
Yes n = 61 74.39(12.24) 74.59(15.01) 76.64(13.75) 76.64(17.79) 82.62(15.04) 63.61(17.06)
No n = 216 77.01(11.11) 78.73(14.85) 75.64(12.27) 75.21(16.34) 83.84(14.61) 69.21(15.67)
P-value 0.214 0.051 0.759 0.343 0.601 0.026
*subcutaneous injection treatment
Table 7 Relationship between quality of life scores and patient characteristics by Pearson’s correlation coefficient
Pearson’s correlation coefficient
Total summary
score
Physical
health
Psychosocial
health
Emotional
functioning
Social
functioning
School
functioning
Serum ferritin level (ng/
mL)
-0.061 -0.091 -0.052 0.444 -0.043 -0.088
Pre-transfusion Hb level
(g/dL)
0.170* 0.105 0.123** 0.009 0.222* 0.184*
Age (years) 0.250* 0.163* 0.185* 0.175* 0.217* 0.198*
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adulthood presents many new challenges - a more inde-
pendent lifestyle, choosing a successful career path, and
marriage [32] - this study found that adolescent patients
had significantly higher HRQOL than their younger
counterparts. This finding was similar to that of a pre-
vious study which revealed that older children with tha-
lassemia experienced fewer symptoms of depression,
reflecting a process of adjustment and coping [6].
Although existing evidence indicates that long-term
iron overload might result in severe morbidity and mor-
tality [15,16,28,38], and that a serum ferritin level higher
than 2,500 ng/dL is associated with cardiac complica-
tions and mortality [15], this study found no relation-
ship between serum ferritin level and HRQOL. This
contradictory result could possibly be due to the fact
that damaging, long-term iron overload occurs gradu-
ally; so short-term iron overload, as represented by an
elevated serum ferritin level, did not cause significant
visible symptoms or complications, and hence had no
impact on their HRQOL. Similar to the findings of pre-
vious studies [13,14], this study found that, due to the
burden of nightly subcutaneous injections of desferriox-
amine 5 to 7 days per week [29], iron chelation treat-
ment was significantly related to impaired HRQOL.
Complications and type of diagnosis were not related
to HRQOL level in this study. This could be because
the number of patients having complications was too
small (only 6.1%) to detect a significant difference. Simi-
larly, although patients diagnosed with homozygous b-
thalassemia were expected to have significantly lower
HRQOL since they were transfusion-dependent, a non-
significant relationship between type of diagnosis and
HRQOL was found in this study. This could possibly be
due to the small number of patients diagnosed with
homozygous b-thalassemia (< 5%) that were included in
this study. Concordant with the findings from a previous
study conducted on children with thalassemia [11], gen-
der was not associated with HRQOL in this study.
One limitation of this study, as previously mentioned,
is the absence of HRQOL scores of healthy children in
Thailand. As a result, the true magnitude of thalasse-
mia’s impact on HRQOL was hardly estimated. Other
limitation is that purposive sampling of the settings
might limit the extent to which the results could be
extrapolated to patients in other settings. In addition,
failure to recruit adequate subjects, as stated in sample
size calculation may be a potential limitation of the
study. Lastly, as there was no consensus on how to
determine severity of thalassemia patient, the criteria to
assess severity of thalassemia varied across studies, ran-
ging from only referred to patients with homozygous b
thalassemia [39] to other different criteria [30,40,41]. As
the result, the direct comparison across studies should
be made with caution. The definition of severity used in
this study was developed based on local expert opinions.
As only data on type of diagnosis, hemoglobin level, age
o n s e to fa n e m i a ,a n da g ea tfirst transfusion were
required to assess severity, this definition seemed to be
feasible in less developed countries, where data on
laboratory value or genetic information were unavailable
in general practice.
Conclusion
The findings of this study highlight the significant nega-
tive impact of thalassemia and its treatment on HRQOL
in terms of physical functioning and psychosocial func-
tioning, especially in the school functioning subscale. In
light of this, and considering the prevalence of thalasse-
mia in Thailand, our study suggested that modification
of existing thalassemia management could be beneficial.
Psychosocial and counseling programs aimed at helping
patients discuss and accept their illness, facilitating a
normal lifestyle, and providing a link between patients,
s c h o o lo f f i c i a l s ,t h ef a m i l ya n dt h ep h y s i c i a nm a yb e
helpful in alleviating these difficulties, especially aca-
demic performance. In addition, modification of health
care services for children with thalassemia to become
more patient-centered, flexible and comprehensive may
reduce time spent at hospitals and also improve treat-
ment outcomes, including HRQOL of the patients.
In the meantime, while stem cell transplantation is not
considered as a standard treatment, blood transfusion
and iron chelation therapy are required for thalassemia
patients. The findings of this study confirmed the
importance of maintaining pre-transfusion Hb level
above 9 g/dL. Therefore, effective strategies aimed at
promoting access to blood transfusions should be
employed in several developing countries, where at pre-
sent there is limited access to this essential treatment.
In addition, given the fact that long-term iron overload
leads to severe complications and increase mortality, a
more convenient regimen of iron chelation that would
prevent the long-term consequences of iron overload is
essential and could help improve HRQOL of the patient
[40-42], even in the situation where no significant rela-
tionship between the elevation of serum ferritin and
HRQOL is found.
Table 8 Multivariate regression analysis results
b SE (b) P-value
Constant 4.231 0.028 <0.001
Having a severe condition* -0.162 0.017 0.003
Age (years) 0.243 0.003 <0.001
R
2 = 0.089, Y = Ln (total summary score)
* Patients whose age at onset <2 and age at first transfusion <4 years, and/or
patients diagnosed with homozygous b-thalassemia, and/or patients with a
pre-transfusion Hb level < 7 g/dL.
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Page 8 of 10Furthermore, patients whose age at onset of anemia
<2 years and age at first transfusion <4 years; those
receiving blood transfusions whose pre-transfusion Hb
<7 g/dL; those receiving iron chelation therapy; and
those diagnosed with homozygous b-thalassemia deserve
special attention and proactive care, since their HRQOL
scores were relatively low.
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